Navigation Links
Molecular Diagnostics: Technologies, Markets and Companies - 2013 Report
Date:7/25/2013

DUBLIN, July 25, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/7l6fw7/molecular) has announced the addition of the new report "Molecular Diagnostics - Technologies, Markets and Companies" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reactions (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.

Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions, is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for point-of-care and biowarfare agents such as anthrax.

The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 800 companies have been identified to be involved in developing molecular diagnostics and 333 of these are profiled in the report along with tabulation of 779 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.

The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2012 according to technologies, applications and geographical regions. Forecasts are made up to 2022. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.

Benefits of this report

- This report has evolved during the past 17 years, profiting from feedback by numerous readers and experts.

- The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.

- Includes profiles of 333 companies, the largest number in any report on this topic.

- 600 references, cited in the report are included in the bibliography.

- The text is supplemented by 101 tables and 16 figures.

Who should read this report?

- Chief executive officers of molecular diagnostic companies.

- Business development executives of pharmaceutical and biotechnology companies.

- Executives of companies involved in developing integration of diagnosis and treatment as well as those interested in personalized medicine.

- Officers of genomic and proteomic companies interested in diagnostic technologies.

- Research scientists involved in application of molecular diagnostic technologies.

- Planners of healthcare services.

Key Topics Covered:

Part I: Technologies & Applications

Executive Summary

1. Introduction

2. Molecular Diagnostic Technologies

3. Biochips, Biosensors, and Nanobiotechnology

4. Proteomic Technologies for Molecular Diagnostics

5. Molecular Diagnosis of Genetic Disorders

6. Molecular diagnosis of cardiovascular disorders

7. Molecular Diagnosis of Infections

8. Molecular Diagnosis of Cancer

9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare

10. Molecular Diagnostics in Forensic Medicine and Biological Warfare

11. References

Part II: Regulations, Markets & Companies

12. Ethics, Patents and Regulatory issues

13. Markets for Molecular Diagnostics

14. Companies involved in molecular diagnostics

For more information visit http://www.researchandmarkets.com/research/7l6fw7/molecular

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Diagnostics


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Molecular Biomarkers for Cancer Detection and Management
2. Managing Antibiotic-Resistant Bloodstream Infections with Rapid Molecular Diagnostics educational webinar hosted by Nanosphere and Xtalks
3. The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools
4. NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI
5. Understanding the molecular mechanisms underlying Alzheimers disease
6. Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript
7. Caris Life Sciences ASCO Presentation Highlights the Utility of Molecular Profiling for the Management of Rare and Aggressive Cancers
8. Maryville, Tennessee Based Molecular Pathology Laboratory Network (MPLN) Celebrates 38th Annual Medical Laboratory Professional Week by Honoring Employees
9. Researchers untangle molecular pathology of giant axonal neuropathy
10. Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing
11. Molecular Recognition Elements in Sensing Applications - Biodetection Technologies 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  The National Pharmaceutical ... joined the health policy research organization as its newest ... and Regulatory Affairs ( North America ), ... of Directors. "We,re pleased to have Ipsen ... President Dan Leonard . "We welcome their insights ...
(Date:3/28/2017)... 2017 Dr. Chris Yu , ... Anpac Bio-Medical Science Company , announced this ... processing and reporting over 40,000 cases worldwide of ... liquid biopsy tests. Described as ... publications, Anpac Bio,s CDA medical devices and technology ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of LabKey’s newest software solution, LabKey Biologics . Built in collaboration ... and biotech organizations, LabKey Biologics provides drug research teams tools for biological entity ...
(Date:3/28/2017)... NEW YORK , March 28, 2017 /PRNewswire/ ... a highly volatile and unpredictable sector due to ... space. Markets served include medical, agricultural, environmental, and ... these four stocks: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), ... OCRX), and Ocular Therapeutix Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):